

Richard Haynes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2959438/publications.pdf>

Version: 2024-02-01

86
papers

19,018
citations

136740

32
h-index

62479

80
g-index

99
all docs

99
docs citations

99
times ranked

31763
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Dexamethasone in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 693-704. | 13.9 | 8,063 |
| 2 | Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1330. | 3.8 | 1,855 |
| 3 | Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. <i>New England Journal of Medicine</i> , 2014, 371, 203-212. | 13.9 | 1,367 |
| 4 | Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 2030-2040. | 13.9 | 1,013 |
| 5 | Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2018, 379, 1529-1539. | 13.9 | 823 |
| 6 | Lopinavirâ€“ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2020, 396, 1345-1352. | 6.3 | 569 |
| 7 | Effects of nâˆ³ Fatty Acid Supplements in Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2018, 379, 1540-1550. | 13.9 | 510 |
| 8 | Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12â€™064 survivors of myocardial infarction: a double-blind randomised trial. <i>Lancet, The</i> , 2010, 376, 1658-1669. | 6.3 | 501 |
| 9 | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 499. | 3.8 | 498 |
| 10 | Effects of Homocysteine-Lowering With Folic Acid Plus Vitamin B₁₂ vs Placebo on Mortality and Major Morbidity in Myocardial Infarction Survivors. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 2486. | 3.8 | 283 |
| 11 | Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. <i>Lancet Diabetes and Endocrinology, the</i> , 2016, 4, 829-839. | 5.5 | 234 |
| 12 | The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 749-761. | 1.4 | 196 |
| 13 | Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. <i>Circulation</i> , 2018, 138, 1505-1514. | 1.6 | 145 |
| 14 | Effects of Lowering LDL Cholesterol on Progression of Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1825-1833. | 3.0 | 142 |
| 15 | Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2015-2027. | 3.0 | 140 |
| 16 | Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. <i>Lancet, The</i> , 2014, 384, 1684-1690. | 6.3 | 124 |
| 17 | What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. <i>BMC Nephrology</i> , 2015, 16, 65. | 0.8 | 82 |
| 18 | Neprilysin inhibition in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 738-743. | 0.4 | 80 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | ASCEND: A Study of Cardiovascular Events in Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. <i>American Heart Journal</i> , 2018, 198, 135-144. | 1.2 | 78 |
| 20 | The role of lipoprotein (a) in chronic kidney disease. <i>Journal of Lipid Research</i> , 2018, 59, 577-585. | 2.0 | 77 |
| 21 | The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2016, 68, 591-598. | 2.1 | 74 |
| 22 | Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e001696. | 1.6 | 65 |
| 23 | International consensus definitions of clinical trial outcomes for kidney failure: 2020. <i>Kidney International</i> , 2020, 98, 849-859. | 2.6 | 65 |
| 24 | Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1317-1329. | 0.4 | 58 |
| 25 | Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016, 68, 371-380. | 2.1 | 57 |
| 26 | Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2014, 64, 40-48. | 2.1 | 55 |
| 27 | Evidence for the Prevention and Treatment of Stroke in Dialysis Patients. <i>Seminars in Dialysis</i> , 2015, 28, 35-47. | 0.7 | 49 |
| 28 | Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. <i>American Journal of Kidney Diseases</i> , 2016, 67, 31-39. | 2.1 | 42 |
| 29 | Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 546-552. | 2.2 | 41 |
| 30 | Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 47-60. | 2.2 | 41 |
| 31 | Chronic kidney disease, heart failure and neprilysin inhibition. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 558-564. | 0.4 | 39 |
| 32 | Conventional and Genetic Evidence on the Association between Adiposity and CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 127-137. | 3.0 | 39 |
| 33 | Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad hoc task force on sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2021, 23, 1260-1275. | 2.9 | 36 |
| 34 | Serum Free Light Chains and the Risk of ESRD and Death in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2829-2837. | 2.2 | 35 |
| 35 | Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events in Diabetes (ASCEND). <i>Trials</i> , 2016, 17, 286. | 0.7 | 34 |
| 36 | Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. <i>EclinicalMedicine</i> , 2021, 41, 101163. | 3.2 | 33 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. <i>Kidney International</i> , 2018, 93, 1000-1007. | 2.6 | 32 |
| 38 | Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease. <i>Hypertension</i> , 2017, 69, 314-322. | 1.3 | 30 |
| 39 | Late presentation of patients with end-stage renal disease for renal replacement therapy—is it always avoidable?. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3646-3651. | 0.4 | 27 |
| 40 | Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. <i>European Heart Journal</i> , 2020, 41, 3336-3342. | 1.0 | 27 |
| 41 | Effect of Processing Delay and Storage Conditions on Urine Albumin-to-Creatinine Ratio. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1794-1801. | 2.2 | 22 |
| 42 | Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol. <i>Transplantation Research</i> , 2013, 2, 7. | 1.5 | 21 |
| 43 | A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. <i>Heart</i> , 2017, 103, 1880-1890. | 1.2 | 21 |
| 44 | Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy. <i>Kidney International</i> , 2018, 93, 1165-1174. | 2.6 | 21 |
| 45 | The Effect of Lowering LDL Cholesterol on Vascular Access Patency. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 914-919. | 2.2 | 19 |
| 46 | Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016, 67, 576-584. | 2.1 | 19 |
| 47 | Biliary Tract and Liver Complications in Polycystic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2738-2748. | 3.0 | 19 |
| 48 | Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) — results of a randomized controlled clinical trial. <i>American Journal of Transplantation</i> , 2018, 18, 1424-1434. | 2.6 | 18 |
| 49 | Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. <i>European Heart Journal</i> , 2022, 43, 2010-2019. | 1.0 | 18 |
| 50 | Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes. <i>JAMA Network Open</i> , 2019, 2, e190223. | 2.8 | 16 |
| 51 | Effects of Omega-3 Fatty Acid Supplements on Arrhythmias. <i>Circulation</i> , 2020, 141, 331-333. | 1.6 | 15 |
| 52 | Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial-Adjudicated Direct Follow-up Data in the UK. <i>JAMA Network Open</i> , 2021, 4, e2139748. | 2.8 | 15 |
| 53 | LIPIDS IN CHRONIC KIDNEY DISEASE. <i>Journal of Renal Care</i> , 2010, 36, 27-33. | 0.6 | 14 |
| 54 | Survival after Starting Renal Replacement Treatment in Patients with Autosomal Dominant Polycystic Kidney Disease: A Single-Centre 40-Year Study. <i>Nephron Clinical Practice</i> , 2012, 120, c42-c47. | 2.3 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Kidney disease trials for the 21st century: innovations in design and conduct. <i>Nature Reviews Nephrology</i> , 2020, 16, 173-185. | 4.1 | 14 |
| 56 | Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. <i>Kidney International</i> , 2019, 96, 170-179. | 2.6 | 13 |
| 57 | Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2â€“Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial. <i>Clinical Therapeutics</i> , 2019, 41, 1767-1777. | 1.1 | 12 |
| 58 | Myeloma Kidney: Improving Clinical Outcomes?. <i>Advances in Chronic Kidney Disease</i> , 2012, 19, 342-351. | 0.6 | 11 |
| 59 | PCSK9 inhibition: ready for prime time in CKD?. <i>Kidney International</i> , 2018, 93, 1267-1269. | 2.6 | 11 |
| 60 | Feasibility of Telemonitoring Blood Pressure in Patients With Kidney Disease (Oxford Heart and Renal) Tj ETQqO O 0 rgBT /Overlock 10 Tt | 0.7 | 10 |
| 61 | Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank. <i>International Journal of Obesity</i> , 2020, 44, 2256-2266. | 1.6 | 9 |
| 62 | TaleNepriylsin and Nepriylsin inhibition in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 123-130. | 1.0 | 9 |
| 63 | Dual blockade of the renin-angiotensin system: are two better than one?. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3602-3607. | 0.4 | 8 |
| 64 | Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 348-354. | 0.9 | 8 |
| 65 | Proteinuria. <i>BMJ: British Medical Journal</i> , 2006, 332, 284. | 2.4 | 7 |
| 66 | How the NHS research governance procedures could be modified to greatly strengthen clinical research. <i>Clinical Medicine</i> , 2010, 10, 127-129. | 0.8 | 7 |
| 67 | Niacin for Reduction of Cardiovascular Risk. <i>New England Journal of Medicine</i> , 2014, 371, 1940-1944. | 13.9 | 7 |
| 68 | Homocysteine, the kidney, and vascular disease. <i>BMJ, The</i> , 2012, 344, e3925-e3925. | 3.0 | 6 |
| 69 | Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, gfw396. | 0.4 | 6 |
| 70 | Does serum phosphate predict death and ESRD in CKD patients?. <i>Nature Reviews Nephrology</i> , 2013, 9, 438-439. | 4.1 | 5 |
| 71 | Statins in chronic kidney disease: time to move on?. <i>Nature Reviews Nephrology</i> , 2015, 11, 262-263. | 4.1 | 5 |
| 72 | Cardiovascular Aspects of Kidney Disease. , 2012, , 2059-2080. | | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Aspirin for primary prevention of vascular disease in people with diabetes. <i>BMJ: British Medical Journal</i> , 2009, 339, b4596-b4596. | 2.4 | 4 |
| 74 | Alemtuzumab: right drug, right dose?*. <i>Transplant International</i> , 2011, 24, 1051-1052. | 0.8 | 3 |
| 75 | Investigating modifications to participant information materials to improve recruitment into a large randomized trial. <i>Trials</i> , 2019, 20, 681. | 0.7 | 3 |
| 76 | Tocilizumab in COVID-19 therapy: who benefits, and how? â€“ Authors' reply. <i>Lancet, The</i> , 2021, 398, 300. | 6.3 | 3 |
| 77 | Quiz Page September 2013. <i>American Journal of Kidney Diseases</i> , 2013, 62, A26-A29. | 2.1 | 2 |
| 78 | Reassuring results with regard to the effect of donor nephrectomy on cardiovascular outcomes. <i>Nature Reviews Nephrology</i> , 2009, 5, 126-127. | 4.1 | 1 |
| 79 | Screening for risk with albuminuria: should we start from here?. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3463-3465. | 0.4 | 1 |
| 80 | Outcomes of Elderly Patients with Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis Treated with Immunosuppressive Therapy. <i>Nephron</i> , 2016, 133, 223-231. | 0.9 | 1 |
| 81 | Niacin: old habits die hard. <i>Heart</i> , 2016, 102, 170-171. | 1.2 | 1 |
| 82 | Fluvastatin for reduction of cardiovascular risk in patients with moderate to severe renal insufficiency. <i>Nature Clinical Practice Nephrology</i> , 2007, 3, 530-531. | 2.0 | 0 |
| 83 | Clinical trials of lipid-modifying agents: design considerations. <i>Clinical Lipidology</i> , 2011, 6, 109-116. | 0.4 | 0 |
| 84 | Alemtuzumab induction therapy in kidney transplantation â€“ Authors' reply. <i>Lancet, The</i> , 2015, 385, 771. | 6.3 | 0 |
| 85 | Use of gel-based separator tubes to stabilise phosphate in mailed blood samples. <i>Clinica Chimica Acta</i> , 2015, 439, 112-114. | 0.5 | 0 |
| 86 | Haemodialysis, blood pressure and risk: at the limit of non-randomized evidence. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1465-1468. | 0.4 | 0 |